Home Cart Sign in  
Chemical Structure| 339163-65-4 Chemical Structure| 339163-65-4

Structure of RCM-1
CAS No.: 339163-65-4

Chemical Structure| 339163-65-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

RCM-1 is a FOXM1 inhibitor.

Synonyms: Robert Costa Memorial drug-1

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of RCM-1

CAS No. :339163-65-4
Formula : C20H12N2OS4
M.W : 424.58
SMILES Code : N#CC1=C(SCC(C2=CC=CS2)=O)N=C(C3=CC=CS3)C=C1C4=CC=CS4
Synonyms :
Robert Costa Memorial drug-1
MDL No. :MFCD00742440
InChI Key :DCCYTKKDAZEVLY-UHFFFAOYSA-N
Pubchem ID :4273985

Safety of RCM-1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
BGC823 cells 10 μM 24 h RCM-1 enhances the interaction between RNF112 and FOXM1 PMC10259508
MGC803 cells 10 μM 24 h RCM-1 enhances the interaction between RNF112 and FOXM1 PMC10259508
mouse pancreatic adenocarcinoma KPC-2 cells 20 μM 24, 48, 72 h To assess the effect of RCM-1 on cancer cell proliferation, results showed that RCM-1 significantly inhibited the growth of KPC-2 cells PMC7341442
mouse prostate adenocarcinoma MyC-CaP cells 20 μM 24, 48, 72 h To assess the effect of RCM-1 on cancer cell proliferation, results showed that RCM-1 significantly inhibited the growth of MyC-CaP cells PMC7341442
mouse breast carcinoma 4T1 cells 20 μM 24, 48, 72 h To assess the effect of RCM-1 on cancer cell proliferation, results showed that RCM-1 significantly inhibited the growth of 4T1 cells PMC7341442
human lung adenocarcinoma H2122 cells 20 μM 24, 48, 72 h To assess the effect of RCM-1 on cancer cell proliferation, results showed that RCM-1 significantly inhibited the growth of H2122 cells PMC7341442
mouse melanoma B16-F10 cells 20 μM 24, 48, 72 h To assess the effect of RCM-1 on cancer cell proliferation, results showed that RCM-1 significantly inhibited the growth of B16-F10 cells PMC7341442
mouse rhabdomyosarcoma Rd76–9 cells 20 μM 24, 48, 72 h To assess the effect of RCM-1 on cancer cell proliferation, results showed that RCM-1 significantly inhibited the growth of Rd76–9 cells PMC7341442
human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) 1 μM 5 days FOXM1 inhibition promoted maturational characteristics such as increased contractility, oxygen consumption, and voltage peak maximum upstroke velocity. PMC11255683

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Rhabdomyosarcoma Rd76–9 model Intraperitoneally (IP) 20 mg/kg Once daily for 7 days To evaluate the inhibitory effect of RCM-1 on tumor growth, results showed that RCM-1 significantly reduced tumor volume, decreased FOXM1 expression, reduced tumor cell proliferation and increased apoptosis PMC7341442
Nude mice Xenograft tumor model Intraperitoneal injection 20 mg/kg Every 3 days until the sacrifice day RCM-1 inhibits gastric cancer proliferation partially dependent on RNF112 PMC10259508
C57BL/6 mice Diabetic encephalopathy model Oral gavage 0.75 g/kg, 1.5 g/kg, 3 g/kg Once daily for 15 weeks To evaluate the effects of RCM-1 on cognitive function and neuronal injury in diabetic encephalopathy model mice. Results showed that RCM-1 significantly improved cognitive function, alleviated hippocampal neuronal injury, and upregulated the expression of Nav1.1 and Nav1.2. PMC11949989
Mice Hymenolepis nana infection model Intraperitoneal injection 1.7 mg/kg Seven consecutive days RCM-1 inhibited the immune responses induced by H. nana and its excretory-secretory products (ESP), affecting the host's ability to eliminate H. nana PMC11899370

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.36mL

0.47mL

0.24mL

11.78mL

2.36mL

1.18mL

23.55mL

4.71mL

2.36mL

References

 

Historical Records

Categories